Related references
Note: Only part of the references are listed.Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis
Ting Shi et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
The promise of mRNA vaccines: a biotech and industrial perspective
Nicholas A. C. Jackson et al.
NPJ VACCINES (2020)
Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection
Amy S. Espeseth et al.
NPJ VACCINES (2020)
Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years
Kristi Williams et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
An mRNA Vaccine against SARS-CoV-2-Preliminary Report
L. A. Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus
Jessica Marcandalli et al.
CELL (2019)
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
Robert A Feldman et al.
VACCINE (2019)
A proof of concept for structure-based vaccine design targeting RSV in humans
Michelle C. Crank et al.
SCIENCE (2019)
Immunological goals for respiratory syncytial virus vaccine development
Barney S. Graham
CURRENT OPINION IN IMMUNOLOGY (2019)
2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate
Beate Schmoele-Thoma et al.
Open Forum Infectious Diseases (2019)
902. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Healthy Adults
John DeVincenzo et al.
Open Forum Infectious Diseases (2019)
Advances in mRNA Vaccines for Infectious Diseases
Cuiling Zhang et al.
FRONTIERS IN IMMUNOLOGY (2019)
Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials
Jiri Beran et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
A novel method for strict intranasal delivery of non-replicating RSV vaccines in cotton rats and non-human primates
Michael P. Citron et al.
VACCINE (2018)
Vaccines for the elderly: current use and future challenges
Birgit Weinberger
IMMUNITY & AGEING (2018)
Vaccination in the elderly: The challenge of immune changes with aging
Annalisa Ciabattini et al.
SEMINARS IN IMMUNOLOGY (2018)
Establishment of the first WHO International Standard for antiserum to Respiratory Syncytial Virus: Report of an international collaborative study
Jacqueline U. McDonald et al.
VACCINE (2018)
A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant
Joanne M. Langley et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Vaccine development for respiratory syncytial virus
Barney S. Graham
CURRENT OPINION IN VIROLOGY (2017)
Risk of mortality associated with respiratory syncytial virus and influenza infection in adults
Yong Shik Kwon et al.
BMC INFECTIOUS DISEASES (2017)
Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors
Morgan S. A. Gilman et al.
SCIENCE IMMUNOLOGY (2016)
Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera
Joan O. Ngwuta et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
An Overview of Respiratory Syncytial Virus
Jia Meng et al.
PLOS PATHOGENS (2014)
Adults 65 Years Old and Older Have Reduced Numbers of Functional Memory T Cells to Respiratory Syncytial Virus Fusion Protein
Anu Cherukuri et al.
CLINICAL AND VACCINE IMMUNOLOGY (2013)
Viral Shedding and Immune Responses to Respiratory Syncytial Virus Infection in Older Adults
Edward E. Walsh et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
Jason S. McLellan et al.
SCIENCE (2013)
Role of Neutralizing Antibodies in Adults With Community-Acquired Pneumonia by Respiratory Syncytial Virus
Vivian Luchsinger et al.
CLINICAL INFECTIOUS DISEASES (2012)
Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
Margarita Magro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Risk Factors for Respiratory Failure Associated with Respiratory Syncytial Virus Infection in Adults
Coley B. Duncan et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay
Sheri Dubey et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Respiratory syncytial virus infection in elderly and high-risk adults
AR Falsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults
EE Walsh et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Mortality associated with influenza and respiratory syncytial virus in the United States
WW Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Share Paper
